Blau Farmacêutica, Brazil

RD&I Director

Uilberson, is in charge of R&D area at Blau Farmacêutica in Brazil, leads the development of biosimilars for the Brazilian market and other Latin American countries. Its strategic scientific, regulatory and clinical approaches ensure robust biosimilar medicine development pathways. Emphasizing regulatory convergence, it promotes broader access to medicines in Brazil and Latin America. At Blau Farmacêutica, Uilberson leads transformational projects, including monoclonal antibodies biosimilars, driving innovation in healthcare accessibility.


Register for the Biosimilars LatAm – Europe 2024